Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Hematol Oncol ; 28(2): 95-7, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16462582

RESUMO

Juvenile xanthogranuloma (JXG), one of the most common forms of Langerhans-dendritic cell proliferation in young children, usually presents as spontaneously regressing cutaneous lesions. JXG with systemic (extracutaneous) involvement is a rare histiocytic disorder in which significant morbidity and death may occur. The systemic type, especially combined with multiple central nervous system lesions in young children, has a very poor prognosis. The patient described here presented with disseminated disease including lungs, liver, kidneys, ribs, scalp, and central nervous system. The patient was treated with multiagent chemotherapy based on the Langerhans cell histiocytosis II treatment protocol. The regimen used included an additional intrathecal therapy with methotrexate and prednisolone to control central nervous system lesions. The patient was treated for 28 months and has been in remission for almost 5 years.


Assuntos
Doenças do Sistema Nervoso Central/tratamento farmacológico , Mercaptopurina/uso terapêutico , Metotrexato/uso terapêutico , Prednisolona/uso terapêutico , Vimblastina/uso terapêutico , Xantogranuloma Juvenil/tratamento farmacológico , Doenças do Sistema Nervoso Central/cirurgia , Terapia Combinada , Craniotomia , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Lactente , Injeções Espinhais , Hepatopatias/tratamento farmacológico , Pneumopatias/tratamento farmacológico , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Paresia/etiologia , Prednisolona/administração & dosagem , Dermatopatias/tratamento farmacológico , Vimblastina/administração & dosagem , Xantogranuloma Juvenil/cirurgia
2.
Pediatr Hematol Oncol ; 22(8): 699-703, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16251176

RESUMO

The authors report on 2 boys, 11(1/2) and 13 years old, who received allogeneic stem cell transplantation (alloSCT) from their HLA-identical sibling after relapse of stage IV alveolar rhabdomyosarcoma. Both patients were transplanted in a non-remission status. After alloSCT both patients experienced disease progression at the primary tumor location sites and died due to the underlying disease 146 and 379 days after transplantation. The authors conclude that an alloSCT derived graft versus tumor effect might not be effective enough to overcome alveolar rhabdomyosarcoma when transplantation is carried out in a nonremission status.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Rabdomiossarcoma Alveolar/terapia , Adolescente , Criança , Progressão da Doença , Evolução Fatal , Alemanha/epidemiologia , Efeito Enxerto vs Tumor/efeitos dos fármacos , Efeito Enxerto vs Tumor/imunologia , Humanos , Masculino , Estadiamento de Neoplasias , Recidiva , Rabdomiossarcoma Alveolar/diagnóstico , Rabdomiossarcoma Alveolar/imunologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...